<DOC>
	<DOCNO>NCT03015701</DOCNO>
	<brief_summary>To compare daily oral mifepristone v placebo respect time treatment failure patient unresectable meningioma .</brief_summary>
	<brief_title>Mifepristone Meningioma</brief_title>
	<detailed_description>To compare daily oral mifepristone v placebo respect time treatment failure patient unresectable meningioma address issue safety patient population .</detailed_description>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>1 . Patients must histologically documented primary , recurrent residual meningioma unresectable . 2 . Patients must active meningioma , define one following : 1 . Progressive disease within past 2 year . 2 . Recurrent Disease , define reappearance previously completely resected meningioma , within past two year . 3 . New disease , define diagnosis meningioma within previous two year 3 . Patients must measurable evaluable disease document CT MRI scan . 4 . Patients already receive radiotherapy unless radiotherapy inappropriate due tumor location ( ) unless radiotherapy , discussion patient 's physician , refuse . If patient receive prior radiotherapy , treatment must complete one year prior study entry document progressive disease since completion radiotherapy . 5 . Patients must 18 year old , must performance status 02 Southwest Oncology Group criterion . 6 . Patients must receive prior cytotoxic chemotherapy meningioma . 7 . Patients must serum creatinine , SGOT , bilirubin â‰¤ 2 x IULN . 8 . Patients require simultaneous administration corticosteroid cerebral edema must receive stable dose corticosteroid least 4 week prior study entry . 9 . Patients receive antiepileptic medication eligible . However barbiturates avoided possible . 10 . Patients meningiomatosis ( diffuse meningeal infiltration result nonevaluable meningeal thicken ) eligible . However , patient multiple measurable evaluable meningioma tumor mass eligible . 11 . Patients malignant meningioma eligible . Malignant meningioma define meningioma demonstrate hypercellularity , loss architecture , nuclear pleomorphism , numerous mitoses , focal necrosis , brain invasion . 12 . Patients additive ablative modulation sex hormone glucocorticoid pathway within precede 3 month ( include stable corticosteroid therapy cerebral edema ) eligible . Such modulation include limited birth control pill , bilateral oophorectomy orchiectomy , progestational insert , oral vaginal exogenous estrogen , androgen antiandrogens , progestational agonist , tamoxifen , aminoglutethimide , , pDDD , ACTH , glucocorticoids cerebral edema , leuprolides ( LHRH inhibitor ) . Patients must receive prior mifepristone therapy meningioma . 13 . Patients must serious intercurrent medical illness ; , illness opinion investigator would prevent follow study regimen . 14 . Patients clinical adrenal insufficiency require exogenous corticosteroid replacement eligible . 15 . Patients know allergy mifepristone eligible . 16 . Patients base brain , cavernous sinus optic nerve meningiomas visual symptom must formal visual field examination . 17 . Pregnant lactate woman may participate . Premenopausal woman men reproductive potential may participate unless agree use effective local contraceptive method ( condom , diaphragm , IUD ) abstinence 3 month study therapy . 18 . Patients prior concurrent malignancy within precede 5 year , except surgically treat squamous basal cell skin cancer cervical cancer situ , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Unresectable</keyword>
</DOC>